UCUwe Christians

Uwe Christians

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Uwe Christians has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • Jost Klawitter

    Department of Anesthesiology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

    10 shared publications
  • Jelena Klawitter

    C42 Clinical Research and Development, University of Colorado, Aurora

    9 shared publications
  • Touraj Shokati

    C42 Clinical Research and Development, University of Colorado, Anschutz Medical Campus

    4 shared publications
  • Alexander A. Vinks

    Division of Translational and Clinical Pharmacology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA

    3 shared publications
  • Björn Schniedewind

    C42 Clinical Research and Development, University of Colorado, Anschutz Medical Campus

    3 shared publications
  • Claudia Clavijo

    AiC42 Clinical Research & Development, Department of Anesthesiology, University of Colorado Denver, Aurora, Colorado

    2 shared publications

Latest Publications

  • Open Access

    Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons

    by Emily Goel, Megan Erwin, Claire V. Cawthon, Carson Schaff, Nathaniel Fedor, Trevor Rayl, Onree Wilson, Uwe Christians, Thomas C. Register, Randolph L. Geary, et al.

    Background: Drug-coated balloons (DCBs), which deliver anti-proliferative drugs with the aid of excipients, have emerged as a new endovascular therapy for the treatment of peripheral arterial disease. In this study, we evaluated the use of keratose (KOS) as a novel DCB-coating excipient to deliver and retain paclitaxel. Methods: A custom coating method was developed to deposit KOS and paclitaxel on uncoated angioplasty balloons. The retention of the KOS-paclitaxel coating, in comparison to a commercially available DCB, was evaluated using a novel vascular-motion simulating ex vivo flow model at 1 h and 3 days. Additionally, the locoregional biological response of the KOS-paclitaxel coating was evaluated in a rabbit ilio-femoral injury model at 14 days. Results: The KOS coating exhibited greater retention of the paclitaxel at 3 days under pulsatile conditions with vascular motion as compared to the commercially available DCB (14.89 ± 4.12 ng/mg vs. 0.60 ± 0.26 ng/mg, p = 0.018). Histological analysis of the KOS–paclitaxel-treated arteries demonstrated a significant reduction in neointimal thickness as compared to the uncoated balloons, KOS-only balloon and paclitaxel-only balloon. Conclusions: The ability to enhance drug delivery and retention in targeted arterial segments can ultimately improve clinical peripheral endovascular outcomes.


  • A High-throughput HPLC-MS/MS Assay for the Detection, Quantification and Simultaneous Structural Confirmation of 136 Drugs and Metabolites in Human Urine

    by Jacek Klepacki, Baharak Davari, Marion Boulet, Ryan Lizarraga, Uwe Christians

    Due to its superior sensitivity and specificity, multi-analyte high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS) has become the gold standard in clinical toxicology. Although several qualitative and quantitative LC-MS/MS assays on various mass spectrometry platforms have been described in the literature, the majority of these methods either analyze only a limited number of compounds, and/or require tedious and time-consuming sample preparation. A major challenge in urine toxicology screening is the minimization of false negative and false positive results. This was addressed by screening for a comprehensive panel of 136 compounds of importance for pain and drug addiction clinics, using high-end, high-sensitivity, fast-scanning mass spectrometry in combination with simultaneous structural confirmation based on ion ratios. The assay was validated and successfully participated in proficiency challenges. The assay met all predefined acceptance criteria. The lower limit of quantifications ranged from 10 to 100 ng/mL. Inter-day trueness and imprecisions ranged from 73.8 to 116.2% and 2.4 to 20.0%, respectively. The total assay run time was 10 minutes. We developed and successfully validated a robust, sensitive, and specific LC-MS/MS-based urine toxicology screening platform that allows for the addition of drugs to quickly adjust to new clinical needs. To date, more than 3000 clinical samples have successfully been analyzed. Our results also indicated that such a quantitative multi-analyte assay is pushing against the limits of current fast-scanning MS/MS instrumentation and that the number of analytes and their internal standards must be balanced with acceptable sensitivity, reproducibility, structural confirmation, and the ability to reliably quantify, all of which was achieved.


  • Biomarkers in Transplantation—Proteomics and Metabolomics

    by Uwe Christians, Jelena Klawitter, Jost Klawitter

    Modern multianalyte “omics” technologies allow for the identification of molecular signatures that confer significantly more information than measurement of a single parameter as typically used in current medical diagnostics. Proteomics and metabolomics bioanalytical assays capture a large set of proteins and metabolites in body fluids, cells, or tissues and, complementing genomics, assess the phenome. Proteomics and metabolomics contribute to the development of novel predictive clinical biomarkers in transplantation in 2 ways: they can be used to generate a diagnostic fingerprint or they can be used to discover individual proteins and metabolites of diagnostic potential. Much fewer metabolomics than proteomics biomarker studies in transplant patients have been reported, and, in contrast to proteomics discovery studies, new lead metabolite markers have yet to emerge. Most clinical proteomics studies have been discovery studies. Several of these studies have assessed diagnostic sensitivity and specificity. Nevertheless, none of these newly discovered protein biomarkers have yet been implemented in clinical decision making in transplantation. The currently most advanced markers discovered in proteomics studies in transplant patients are the chemokines CXCL-9 and CXCL-10, which have successfully been validated in larger multicenter trials in kidney transplant patients. These chemokines can be measured using standard immunoassay platforms, which should facilitate clinical implementation. Based on the published evidence, it is reasonable to expect that these chemokine markers can help guiding and individualizing immunosuppressive regimens, may be able to predict acute and chronic T-cell–mediated and antibody-mediated rejection, and may be useful tools for risk stratification of kidney transplant patients.


  • Inhalation of two putative Gulf War toxins by mice

    by John E. Repine, Paul Wilson, Nancy Elkins, Jelena Klawitter, Uwe Christians, Ben Peters, Dwight M. Smith

    We employed our inhalation methodology to examine whether biomarkers of inflammation and oxidative stress would be produced in mice following inhalation of aerosols containing carbonaceous particles or the vapor of pesticides prevalent during the first Gulf War. Exposure to two putative Gulf War Illness toxins, fine airborne particles and the pesticide malathion, increased biomarkers of inflammation and oxidative stress in Friend virus B (FVB) female mice. Mice inhaling particles 24 h before had increased lung lavage and plasma Leukotriene B4 (LTB4) (a biomarker of inflammation) and PGF2α (a biomarker of oxidative stress) levels, lung lavage protein and lung lavage lactic dehydrogenase (LDH) levels. These changes were a function of particle density and exposure time. Compared to particle inhalation, mice inhaling malathion 24 h before had small increase in plasma LTB4 and PGF2α levels but no increase in lung lavage LTB4, lung lavage protein, lung lavage LDH, and lung lavage alveolar macrophage (AM) levels compared to unexposed control mice. AM from particle-exposed mice contained phagocytosed particles, while AM from malathion-exposed mice showed no abnormalities. Our results indicate that inhaling particles or malathion can alter inflammatory and oxidative biomarkers in mice and raise the possibility that these toxins may have altered inflammation and oxidative stress biomarkers in Gulf War-exposed individuals.


  • Impact of Laboratory Practices on Interlaboratory Variability in Therapeutic Drug Monitoring of Immunosuppressive Drugs

    by Uwe Christians, Alexander A. Vinks, Loralie J. Langman, William Clarke, Pierre Wallemacq, Teun van Gelder, Varun Renjen, Pierre Marquet, Eric J. Bs Meyer

    The immunosuppressants cyclosporine, tacrolimus, sirolimus, everolimus, and probably also mycophenolic acid require therapeutic drug monitoring (TDM)–guided dosing to ensure that blood concentrations are kept within the target range in transplant patients. Reliable, accurate, and precise test methods are therefore essential to effectively monitor levels and to make proper dose adjustments. Data from proficiency testing programs have shown substantial interlaboratory variability. Only few attempts have been made to study the underlying causes. The aim of this study was to systematically document current practices used for immunosuppressant drug TDM in clinical laboratories and identify methodological and practice differences, which may cause the variability observed among laboratories. Data collection was primarily conducted by a structured Web-based survey. Invitations to participate in the survey were distributed to clinical laboratories providing immunosuppressant drug TDM. Surveys were completed by 76 laboratories in 14 countries. The results of our survey suggest that there are 3 main reasons for interlaboratory variability: (1) lack of standardization of laboratory procedures and workflows starting with sample collection and handling, (2) lack of use of appropriate reference materials (eg, isotope-labeled internal standards for liquid chromatography–tandem mass spectroscopy), and (3) poor compliance with internationally accepted good laboratory practice guidelines (eg, related to quality control, quality assurance, validation, training of personnel). The results of the survey also suggest that interlaboratory variability is a multifactorial problem. Technical-level consensus on laboratory operational procedures, quality systems, and personnel training will be of great importance to improve quality and interlaboratory comparability.


  • Open Access

    Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

    by Touraj Shokati, Nicholas Bodenberger, Holly Gadpaille, Björn Schniedewind, Alexander A. Vinks, Wenlei Jiang, Rita R. Alloway, Uwe Christians

    Here we describe a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay to quantify the immunosuppressant ...


  • Everolimus and sirolimus in transplantation-related but different

    by Jost Klawitter, Björn Nashan, Uwe Christians

    Introduction: The inhibitors of the mammalian target of rapamycin (mTOR) sirolimus and everolimus are used not only as immunosuppressants after organ transplantation in combination with calcineurin...


  • Quantification of the 5-lipoxygenase inhibitor zileuton in human plasma using high performance liquid chromatography–tandem mass spectrometry

    by Phillip Pian, Edward Labovitz, Keith Hoffman, Claudia F. Clavijo, Rachael Rzasa Lynn, Jeffrey L. Galinkin, Alexander A. Vinks, Punam Malik, Uwe Christians


  • Open Access

    Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease

    by Jelena Klawitter, Iram Zafar, Jost Klawitter, Alexander T Pennington, Jacek Klepacki, Berenice Y Gitomer, Robert W Schrier, Uwe Christians, Charles L Edelstein

    We previously demonstrated that lovastatin decreases cyst volume and improves kidney function in the Han:SPRD (Cy/+) rat model of ADPKD. Since endothelial dysfunction and inflammatory activity are evident in patients with ADPKD, we investigated whether lovastatin reduces the inflammation and vascular dysfunction and improves kidney cell energy metabolism of Cy/+ rats.